Written by the AllMyPeptides Research Team
Different Receptors, Different Mechanisms
CJC-1295 and Ipamorelin are both studied in growth hormone axis research, but they work through completely different mechanisms:
- CJC-1295 is a GHRH analogue that binds to the GHRH receptor (GHRHR) on pituitary somatotrophs. It mimics the action of endogenous growth hormone-releasing hormone.
- Ipamorelin is a GHSR agonist that binds to the growth hormone secretagogue receptor (GHSR-1a). It mimics the action of ghrelin, the hunger hormone.
Because they target different receptors, researchers often study them together to explore the full spectrum of GH axis regulation.
Structural Comparison
The two peptides differ significantly in structure:
| Property | CJC-1295 | Ipamorelin |
|---|---|---|
| Type | GHRH analogue | GHRP (selective) |
| Amino acids | 29 + DAC | 5 |
| Receptor | GHRHR | GHSR-1a |
| Signalling | Gs/cAMP | Gq/PLC |
| Has DAC | Yes | No |
Why Researchers Study Them Together
The GH axis has multiple regulatory inputs. By studying CJC-1295 and Ipamorelin together, researchers can:
- Explore how different receptor pathways interact in GH regulation
- Investigate potential additive or synergistic effects on somatotroph activation
- Compare the kinetics of GHRH-mediated vs ghrelin-mediated GH release
- Better model the complex physiology of the GH axis
Each peptide should be reconstituted separately and combined only at the point of use according to your research protocol.
Frequently Asked Questions
Do CJC-1295 and Ipamorelin work the same way?+
Which is better for GH axis research?+
Are both peptides legal in the UK?+
Can they be reconstituted together?+
Related Guides
Products discussed in this guide are for research and laboratory use only. AllMyPeptides does not condone or support misuse of any research materials. Not for human or animal consumption.